{"schema_version":"secwatch.filing_event.v1","accession":"0000816956-26-000006","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.767898+00:00","generated_at":"2026-05-16T07:15:18.057724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS","bullets":["Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.","FY2025 sales $1.3747B (+5.2%); GAAP EPS $1.51 vs $4.25, adjusted EPS $4.59 vs $4.17.","FY2026 guidance: revenue $1.345B-$1.375B (organic constant-currency growth 4.5%-6% ex-gastro), adj. EPS $4.30-$4.45.","International Q4 revenue +17% (reported) vs domestic +1.4%; Orthopedic Surgery segment +13.2%.","GAAP results weighed by ~$60M in Q4 operating charges including optimization and product rationalization."],"urls":{"canonical":"https://secwatch.observer/filing/0000816956-26-000006","json":"https://secwatch.observer/filing/0000816956-26-000006.json","markdown":"https://secwatch.observer/filing/0000816956-26-000006.md","text":"https://secwatch.observer/filing/0000816956-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000006/0000816956-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000006/cnmd-20260128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:15:18.057724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}